Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat ...
In combination, two commonly used heart drugs reverse fat accumulation in the liver, a study in animals has shown.
A new study suggests a combination of cardiovascular drugs, pemafibrate and telmisartan, may reverse fatty liver disease by ...
In recent in-vitro studies, the Company successfully confirmed that its Smart mRNAs designed for pancreatic and liver cancers ...
In a study published in the journal Nature Metabolism, researchers treated male mice on a high-fat diet (HFD) with an inhibitor of mitochondrial transcription (IMT). They found that this shifted the ...
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one-third of the adult population. This disorder is characterized by the ...
Two everyday medications, pemafibrate and telmisartan, could offer a safer, faster route to treating fatty liver disease.
Scientists in Barcelona have identified a potential new treatment for metabolic liver conditions by repurposing pemafibrate ...
High doses of cinnamon, especially in supplements or oils, may interfere with how the body metabolizes medications by activating or inhibiting liver enzymes. These interactions could make medications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback